Guaifenesin
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
- Guaifenesin
- Guaifenesin: From Upper Respiratory Tract Conditions (Rhinitis, Common Cold) to Nasal Cavity Disease
Guaifenesin: From Upper Respiratory Tract Conditions (Rhinitis, Common Cold) to Nasal Cavity Disease
One-Sentence Summary
Guaifenesin is an expectorant originally used for upper respiratory conditions such as allergic rhinitis, common cold, pharyngitis and nasopharyngitis. The TxGNN model predicts it may be effective for nasal cavity disease, but there are currently 0 clinical trials and only 1 publication (a narrative review), so the evidence is indirect.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis, vasomotor rhinitis, pharyngitis, common cold, rhinitis, nasopharyngitis, headache disorder (from the knowledge graph; Singapore licence records contain no approved indication text) |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 18 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, guaifenesin is an expectorant that thins and loosens airway mucus. Its efficacy in respiratory tract conditions is the basis of its current use, and mechanistically it may be applicable to nasal cavity disease with mucus hypersecretion or congestion.
Nasal cavity disease is closely related to guaifenesin's existing indications (allergic rhinitis, vasomotor rhinitis, rhinitis, nasopharyngitis). The prediction is therefore largely an extension of existing uses rather than a true repurposing to a new disease area.
The only supporting paper is a narrative article on respiratory allergies in voice users. It mentions decongestants containing guaifenesin as potentially useful, which is indirect evidence only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12487405 | 2002 | Review | Logopedics, Phoniatrics, Vocology | Treatment strategies for allergic voice patients. Antihistamines are generally avoided, while decongestants with guaifenesin may be useful. Steroids help in perennial allergic symptoms. |
Singapore Market Information
All 18 licences are valid single-ingredient registrations, with none cancelled. The licence records contain no approved indication text. Five main authorisations are listed below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN08969P | Cough Relief Syrup 100 mg/5 ml | Syrup | Not stated in the licence record |
| SIN08411P | Breacol Cough Syrup 100 mg/5 ml | Syrup | Not stated in the licence record |
| SIN14588P | Mucinex Extended Release Tablets 600 mg | Tablet, extended release | Not stated in the licence record |
| SIN14659P | Mucinex Extended Release Tablets 1200 mg | Tablet, multilayer, extended release | Not stated in the licence record |
| SIN12140P | Robitussin EX Syrup 200 mg/10 ml | Syrup | Not stated in the licence record |
Safety Considerations
Contraindication information from the knowledge graph is not label text and should be interpreted with caution. It lists many conditions, including hypertension, liver failure, liver disease, cirrhosis, kidney disease, epilepsy, COPD, peptic and gastric ulcer, inflammatory bowel disease, pancreatitis, porphyria, hypothyroidism, adrenocortical insufficiency (Addison disease), thrombocytopenia, anxiety disorders, insomnia and psychotic disorders. Several of these probably reflect the co-formulated ingredients in combination cough and cold products rather than guaifenesin itself.
No drug interaction records were found.
For label warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but the evidence is limited to a single narrative review with no clinical trials. Nasal cavity disease largely overlaps with guaifenesin's existing uses, so it adds little as a new repurposing direction. Package insert safety information has not been obtained.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website
- Mechanism of action data from DrugBank
- Clearer definition of which nasal cavity conditions are targeted
- Controlled clinical evidence in nasal or sinonasal conditions
Other Predicted Indications (for reference)
| Rank | Predicted Indication | Score | Evidence Level | Comment | |------|------|------|------|------| | 2 | Acute laryngopharyngitis | 99.98% | L5 | Driven by similarity to existing indications; no studies supplied | | 3 | Faucial diphtheria | 99.54% | L5 | No plausible mechanism; likely a false positive | | 4 | Cervical disc degenerative disorder | 99.50% | L5 | No plausible mechanism; likely a model artifact | | 5 | Papillary conjunctivitis | 99.27% | L5 | No known anti-allergic mechanism | | 6 | Tracheal disease | 98.83% | L3 | In vitro data on MUC5AC and mucociliary transport (PMID 23113953); the other paper is a case report with no efficacy evidence | | 7 | Trigeminal autonomic cephalalgia | 98.70% | L5 | No established mechanism | | 8 | Anorectal stricture | 98.63% | L5 | No plausible mechanism | | 9 | Anal polyp | 98.61% | L5 | No biological rationale | | 10 | Punctate epithelial keratoconjunctivitis | 98.48% | L5 | No established mechanism |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.